T. Evans

Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study.

Richard G. White, G. Knight, T. Sumner, 2019, The Lancet. Global health.

The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBV

P. Klenerman, E. Barnes, M. Ansari, 2020, Vaccines.

Inhibition of HIV type 1 infection with a RANTES-IgG3 fusion protein.

V. Planelles, B. Rimel, J. Rosenblatt, 1998, AIDS research and human retroviruses.

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

R. Walker, R. Coler, S. Reed, 2018, npj Vaccines.

Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.

J. Phair, K. Squires, A. Landay, 2002, AIDS research and human retroviruses.

STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection.

D. Portnoy, Chris S. Rae, N. Cadieux, 2018, Cell reports.

A rational vaccine pipeline for tuberculosis.

M. Brennan, T. Evans, M. Stone, 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Adenovirally-Induced Polyfunctional T Cells Do Not Necessarily Recognize the Infected Target: Lessons from a Phase I Trial of the AERAS-402 Vaccine

G. Blatner, J. Sadoff, M. Pau, 2016, Scientific Reports.

STING-Activating Adjuvan ts Elicit a Th 17 Immune Response and Protect against Mycobacterium tuberculosis Infection Graphical

D. Portnoy, Chris S. Rae, N. Cadieux, 2018 .

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

R. Walker, R. Coler, S. Reed, 2018, npj Vaccines.

Phase 1b/2a study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) combined with low-dose nivolumab (LDN) in virally-suppressed patients with CHB on nucleos (t)ide analogues

T. Evans, E. Barnes, 2022, Journal of Hepatology.

Innovative clinical trial designs to rationalize TB vaccine development.

M. Hatherill, M. Snowden, W. Hanekom, 2015, Tuberculosis.